StockNews.com Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy

StockNews.com lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN - Free Report) from a strong-buy rating to a buy rating in a research report released on Monday morning.

Separately, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:SUPN traded down $0.23 on Monday, reaching $32.20. The company had a trading volume of 48,734 shares, compared to its average volume of 477,717. The stock has a market capitalization of $1.80 billion, a P/E ratio of 30.11 and a beta of 0.83. The stock has a 50-day moving average price of $35.26 and a 200 day moving average price of $35.02. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $40.28.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. This represents a 10.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 700 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 in the last quarter. 9.30% of the stock is owned by company insiders.

Remove Ads

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Raiffeisen Bank International AG acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $25,000. GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $42,000. Smartleaf Asset Management LLC raised its stake in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after acquiring an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $52,000. Finally, Headlands Technologies LLC boosted its stake in shares of Supernus Pharmaceuticals by 203.0% in the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,015 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.